Glaukos reported positive results in a clinical trial investigating the safety of the surgical exchange procedure for the iDose TR in subjects who had previously received the implant in a phase 2b clinical trial.
The second administration of iDose TR (travoprost intraocular implant) for IOP reduction in subjects with glaucoma and the removal of the original implant in the prospective, multicenter exchange trial were well tolerated, with the second iDose TR demonstrating a favorable safety profile over 12 months, according to a company press release. The average time from administration of the